glp 1 and sibo semaglutide Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgrowth Associated with Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: A Global Retrospective Will Gut Microbiota Help Design
Description
Many people use GLP-1s to lose weight, treat type 2 diabetes, and/or manage other long-term health conditions
Received: Dec 15, 2020
The parallel is striking
In the United States, approximately 42% of adults have obesity [2], and obesity-related costs are estimated at $173 billion annually [3]
